Rachel A. Kudgus

Mayo Clinic — United States

Medicine · Health Sciences

17h-index2.5kcitations58works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(20), Nanoparticle-Based Drug Delivery(14), Cancer Treatment and Pharmacology(9), Ovarian cancer diagnosis and treatment(8), Cancer therapeutics and mechanisms(8)

Publications58 total

Supplementary Figure S2 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Supplementary Figure S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Supplementary Figure S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Supplementary Figure S2 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
Supplementary Table S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
2024Open Access
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
Clinical Cancer Research·2024· 12 citedOpen Access
Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer’s disease pathology and cognition in APP/PS1 female mice
Communications Biology·2024Open Access
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer
npj Breast Cancer·2023· 10 citedOpen Access
Supplemental Figure 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
Supplemental Table 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)
2023Open Access
Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)
2023Open Access
Supplemental Table 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
Data from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
Data from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
Supplemental Figure Legends from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Joel M. Reid(40), John M. Maris(15), Elizabeth Fox(14), Renee M. McGovern(13), Brenda J. Weigel(11), Steven G. DuBois(11), Araz Marachelian(11), Susan Groshen(11), Rochelle Bagatell(11), Lars M. Wagner(11), Randall A. Hawkins(11), Jesse Courtier(11), Hollie Lai(11), Fariba Goodarzian(11), Hiroyuki Shimada(11), Scarlett Czarnecki(11), Denice Tsao‐Wei(11), Katherine K. Matthay(11), Yaël P. Mossé(11), Najee Boucher(10)